广州医药 ›› 2022, Vol. 53 ›› Issue (3): 100-103.DOI: 10.3969/j.issn.1000-8535.2022.03.023

• 论著 • 上一篇    下一篇

阿立哌唑血药浓度/剂量比影响因素分析及临床应用

钟璐莲1, 陈政1, 彭陈陈2, 王娟1, 盛小茜1, 曾环思2, 李裕基1   

  1. 1 深圳市精神卫生中心/深圳市康宁医院 药学部(深圳 518118)
    2 深圳市精神卫生研究所/深圳市康宁医院(深圳 518118)
  • 收稿日期:2021-09-05 出版日期:2022-05-20 发布日期:2022-07-01
  • 基金资助:
    广东省高水平临床重点专科(深圳市配套建设经费)(SZGSP013)

Analysis of influential factors on serum concentration/dose ratio of aripiprazole and clinical application

ZHONG Lulian1, CHEN Zheng1, PENG Chenchen2, WANG Juan1, SHENG Xiaoxi1, ZENG Huansi2, LI Yuji1   

  1. 1 Department of Pharmacy, Shenzhen Mental Health Center/Shenzhen Kangning Hospital, Shenzhen 518118,China
    2 Shenzhen Mental Health Institute/Shenzhen Kangning Hospital, Shenzhen 518118,China
  • Received:2021-09-05 Online:2022-05-20 Published:2022-07-01

摘要: 目的 探讨性别、年龄、日剂量、合并用药、药物厂家等因素对使用阿立哌唑患者稳态血药浓度的影响,为临床合理用药提供依据。方法 收集深圳市康宁医院2019年1月—2021年2月使用阿立哌唑住院患者血药浓度监测数据样本229份,包括患者性别、年龄、日剂量、合并用药、药物厂家等基本信息,使用SPSS 25.0统计学软件对数据进行回顾性分析。结果 经多元线性回归分析,本研究仅性别、日剂量能解释阿立哌唑血药浓度的变化。使用阿立哌唑患者血药浓度剂量比值(C/D)女性组高于男性组(P<0.01),阿立哌唑合用丙戊酸盐组高于无合用组(P<0.05),年龄、其他合并、药物厂家用药对阿立哌唑(C/D)值的影响无统计学差异。结论 阿立哌唑C/D值与性别有关,合并用药对其有一定影响,不同药物厂家的阿立哌唑C/D值无统计学差异,临床应加强治疗药物监测,根据血药浓度及临床诊疗效果,结合药物经济学因素优化给药方案。

关键词: 阿立哌唑, 血药浓度, 治疗药物监测, 合理用药

Abstract: Objective To provide the reference for clinical rational use of aripiprazole,to investigate the effects of gender, age, daily dose, concurrent medication, drug manufacturer and other factors on the steady-state serum concentration in aripiprazole patients. Methods Serum concentration monitoring data of 229 inpatients using aripiprazole in Shenzhen Kangning Hospital from January 2019 to February 2021 was collected, including patients' gender, age, daily dose, concurrent medication, drug manufacturer and other basic information, which were retrospectively analyzed by SPSS 25.0 statistical software. Results In this study, only gender and daily dose could explain the significant changes of aripiprazole serum concentration after multiple linear regression analysis. The serum concentration/dose ratio (C/D) was significantly higher in female patients than in male patients (P<0.01), and the group of aripiprazole combined with valproate was markedly higher than the non-combined group (P<0.05). Nevertheless, there were no statistically significant differences in the effects of age, concurrent medication and drug manufacturer on aripiprazole C/D values. Conclusions The C/D value of aripiprazole was closely related to gender, and concurrent medication had a certain effect on it. There was no statistical difference in the aripiprazole C/D value among different drug manufacturers. This study suggested that clinical monitoring of therapeutic drugs should be strengthened, and the prescription should be optimized based on serum concentration and therapeutic efficacy, combined with pharmacoeconomic factors.

Key words: aripiprazole, serum concentration, therapeutic drug monitoring, rational drug use